胶质母细胞瘤
Glioblastoma
定义 英文原文（暂无中文）
Glioblastomas are malignant astrocytic tumors (grade IV according to the WHO classification).
别名
多形性胶质母细胞瘤
基本事实
- 遗传方式
- 多基因/多因素、不适用
- 发病年龄
- 各年龄段
- 患病率
- 1-9 / 100 000
相关基因 1来自下位疾病
Orphanet 未在本条目上直接标注致病基因。下表由本组所属的下位疾病汇总而来，「来源条目」列给出基因实际标注在哪一个 ORPHA 条目上。
| 基因 | 名称 | 来源条目 |
|---|---|---|
| LZTR1 | leucine zipper like post translational regulator 1 | ORPHA:251576 |
临床表型 15
必现 100%1
- 多形性胶质母细胞瘤 HP:0012174
极常见 99–80%1
- 细胞形态异常 HP:0025461
常见 79–30%11
- 脑白质形态异常 HP:0002500
- 胼胝体形态异常 HP:0001273
- 神经系统生理功能异常 HP:0012638
- 脑水肿 HP:0002181
- 情绪不稳 HP:0000712
- 疲乏 HP:0012378
- 头痛 HP:0002315
- 语言障碍 HP:0002463
- 肌无力 HP:0001324
- 瘫痪 HP:0003470
- 视力丧失 HP:0000572
偶见 29–5%2
- 记忆障碍 HP:0002354
- 癫痫发作 HP:0001250
近两年的全球研究 39,619L2
2024/08 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。
- 2026-07Ultrasound-triggered platelet vehicles loading fluorescein for targeted sonodynamic therapy of glioblastoma
- 2026-07Single-cell transcriptome-guided biomimetic magnetothermal hydrogel microspheres for multimodal eradication of residual glioblastoma
- 2026-07HSV-1 induced autophagy-associated DPD degradation promotes antitumor efficacy of oncolytic HSV-CD/5-FC in experimental glioblastoma
- 2026-07综述Emerging bioactive microneedle platforms for disease management: From cutaneous disorders to systemic therapeutics
- 2026-07Trichodermin exhibits potent anti-glioblastoma activity by inducing cell cycle arrest and apoptosis, suppressing invasion, and enhancing temozolomide efficacy
- 2026-07Exploratory multi-omics links CCL2/TIMP1 axis to immunosuppressive TME in glioblastoma
- 2026-07综述Biomimetic membrane-coated metal nanoplatforms for enhanced BBB penetration and targeted glioblastoma therapy
- 2026-07病例报告The clinical utility of magnetic resonance elastography in differentiating tumor recurrence from pseudoprogression in glioblastoma
- 2026-07综述Genomic and chromosomal Instability: Hidden drivers of Glioblastoma aggressiveness
- 2026-07综述Gut microbiome-mediated modulation of the glioblastoma tumor microenvironment for enhanced immunotherapy response: Mechanistic insights and future perspectives
- 2026-07Synthesis and biological investigation of phenothiazine-based derivatives as potential HDAC6 inhibitors for treatment of glioblastoma multiforme
- 2026-06综述Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles
- 2026-06开放获取Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study
- 2026-06开放获取Health literacy, medication adherence, and quality-of-life scores in Jordanian adults with chronic diseases: a dual analytical study using the long-term conditions questionnaire and the EuroQol five-dimension three-level questionnaire
- 2026-06开放获取Risk stratification for in-hospital mortality in sepsis-associated acute kidney injury patients receiving continuous renal replacement therapy: an interpretable, externally validated machine learning study
- 2026-06开放获取STARD10 promotes progression of HER2+ breast cancer and intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling axis
- 2026-06系统综述综述开放获取Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review
- 2026-06综述开放获取Synthetic biology of oncolytic bacteria: Comparative microbial chassis and precise killing strategies
- 2026-06综述开放获取Significance of GSH and H<sub>2</sub>S regulation for cancer: an intricate interplay between diet, microbiota, metabolic reprogramming, and immune health
- 2026-06开放获取Predicting long-term allograft outcomes in kidney transplant recipients using a machine learning approach: a 5-year retrospective cohort study
国家医保药品目录中点名本病的药品 1L2
出自《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》（医保发〔2025〕33号，2026-01-01 起执行）。下列药品在药品名称或限定支付范围里出现了本病的名称。
匹配不到 ≠ 不能报销。目录里只有约一成药品设了限定支付范围，其余按适应症正常使用同样可报销；本区块只能回答「目录有没有点名这个病」，不能回答「这个病有没有药能报销」。各省执行细则、双通道与单独支付范围另有规定，请以当地医保部门口径为准。
- 伯瑞替尼肠溶胶囊乙类谈判药品限：1.具有间质-上皮转化因子(MET)外显子14跳变的局部晚期或转移性非小细胞肺癌患者；2.具有间质-上皮转化因子(MET)扩增的局部晚期或转移性非小细胞肺癌患者；3.既往治疗失败的具有PTPRZ1-MET融合基因的IDH突变型星形细胞瘤(WHO4级)或有低级别病史的胶质母细胞瘤成人患者。
境外已获批用于本病的药物 2L2
欧盟 2 项、美国 0 项。同一药物在两地各批一次的，会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径，各有各的条件与费用。这一节能确定地告诉你的只有一件事：这个病在世界范围内已经有获得批准的药物，它叫什么名字。拿这个名字去问主治医生，是下一步最省力的做法。
药名一律保留英文原文，不作翻译——中国的药品通用名与英文名的音译经常不一致，译错会让人去找一个不存在的药。
- Temodal欧盟1999-01-26temozolomide官方记录
- Carmustine medac (previously Carmustine Obvius)欧盟2018-07-18carmustine官方记录
已获孤儿药资格、尚未获批的在研药物（77 项）
孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励，不代表这个药已被证明有效，也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- Sodium Monomercaptoundecahydro-closo-dodecaborate美国1992-04-15For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.官方记录
- Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1美国1999-02-12Treatment of glioblastoma multiforme and anaplastic astrocytoma.官方记录
- Fluorouracil美国2000-06-29Treatment of glioblastoma multiforme.官方记录
- Hypericin美国2000-08-03Treatment of glioblastoma multiforme.官方记录
- 20-mer oligonucleotide complementary to Akt mRNA美国2004-12-08Treatment of glioblastoma官方记录
- 4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)pipe美国2008-07-30Treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme.官方记录
- mibefradil美国2009-08-25Treatment of glioblastoma multiforme.官方记录
- Varbulin美国2009-11-05Treatment of glioblastoma multiforme.官方记录
- dendritic cells pulsed with synthetic peptides derived from antigens M美国2010-06-07Treatment of glioblastoma or brain stem glioma官方记录
- cediranib美国2010-12-13Treatment of glioblastoma官方记录
- vocimagene amiretrorepvec and flucytosine美国2011-01-12Treatment of malignant glioma in addition to glioblastoma multiforme官方记录
- trans sodium crocetinate美国2011-07-21Treatment of glioblastoma in conjunction with radiotherapy官方记录
- paclitaxel poliglumex美国2012-09-20Treatment of glioblastoma multiforme官方记录
- P140K MGMT transduced human CD34 cells美国2013-01-09For bone marrow protection in the treatment of glioblastoma multiforme官方记录
- autologous ex vivo expanded CD4+-enriched leukocytes treated with the 美国2013-09-13Treatment of glioblastoma multiforme官方记录
- [a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsi美国2014-05-14Treatment of glioblastoma multiforme官方记录
- anti-beta1 integrin monoclonal antibody美国2014-08-07Treatment of glioblastoma官方记录
- altiratinib美国2014-08-19Treatment of glioblastoma multiforme.官方记录
- olaptesed pegol美国2014-08-19Treatment of glioblastoma in conjunction with radiotherapy.官方记录
- cannabidiol美国2014-08-20Treatment of glioblastoma multiforme官方记录
- aldoxorubicin美国2014-09-24Treatment of glioblastoma multiforme官方记录
- 8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-美国2015-01-21Treatment of glioblastoma multiforme官方记录
- saposin C美国2015-02-03Treatment of glioblastoma multiforme官方记录
- autologous tumor cells fused with polyethylene glycol to human allogen美国2015-05-06Treatment of glioblastoma官方记录
- chloroquine美国2015-05-20Treatment of glioblastoma multiforme.官方记录
- 2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-dipheny美国2015-06-16Treatment of glioblastoma multiforme.官方记录
- nano-diamino-tetraiodothyroacetic acid美国2015-07-09Treatment of glioblastoma multiforme (GBM)官方记录
- nivolumab美国2015-08-27Treatment of glioblastoma官方记录
- temozolomide美国2015-11-25Treatment glioblastoma multiforme in pediatric patients官方记录
- dodecafluoropentane emulsion (DDFPe)美国2015-12-02Radiosensitizer to be used during radiation treatment of glioblastoma multiforme (GBM).官方记录
- 6-{4-[l-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-y美国2016-02-11Treatment of glioblastoma multiforme (GBM).官方记录
- 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7美国2016-03-29Treatment of glioblastoma官方记录
- human recombinant bone morphogenetic protein 4美国2016-05-04Treatment of glioblastoma multiforme.官方记录
- combination of disulfiram and copper gluconate美国2016-05-18Treatment of glioblastoma multiforme.官方记录
- methimazole and liothyronine sodium美国2016-06-02Treatment of glioblastoma multiforme.官方记录
- 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[美国2016-06-23Treatment of glioblastoma.官方记录
- Autologous dendritic cell/tumor antigens美国2016-09-27Treatment of glioblastoma multiforme (GBM)官方记录
- EnGeneIC delivery vehicles loaded with doxorubicin and targeted to tum美国2017-02-14Treatment glioblastoma multiforme官方记录
- Ritanserin美国2017-05-11Treatment of glioblastoma官方记录
- O,O'-Bis({4-[3,5-diiodo-4-(1-methylene-1,2,3-triazol-4-ylmethoxy)pheno美国2017-06-28Treatment of glioblastoma multiforme官方记录
另有 37 项未列出。
数据来自欧洲药品管理局（EMA）的药品与孤儿药资格公开导出表，以及美国 FDA 孤儿药资格数据库。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。
在中国开展的临床试验 147L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。
登记为可入组 57
- 招募中NCT03005132Integrative Analysis of Human Glioblastoma Multiforme中国研究中心 1 个：Shanghai
- 招募中NCT05990244Magnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion中国研究中心 1 个：Shenyang
- 仅邀请入组NCT03170141Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme中国研究中心 1 个：Shenzhen
- 招募中NCT04267978Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas中国研究中心 1 个：Beijing
- 招募中NCT06595186JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)中国研究中心 1 个：Beijing
- 尚未开始招募NCT05541042Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers中国研究中心 1 个：Zhengzhou
- 尚未开始招募NCT05502991Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma中国研究中心 1 个：Zhengzhou
- 招募中NCT05957679MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment中国研究中心 1 个：Shenyang
- 尚未开始招募NCT05842746Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma中国研究中心 1 个：Beijing
- 招募中NCT05303519SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)中国研究中心 9 个：Beijing、Changsha、Chengdu、Fuzhou、Guangzhou、Shanghai
- 招募中NCT05577091Tris-CAR-T Cell Therapy for Recurrent Glioblastoma中国研究中心 1 个：Beijing
- 尚未开始招募NCT05540275Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma中国研究中心 1 个：Zhengzhou
- 招募中NCT07145047Clinical Study of Oncolytic Virus in Glioblastoma中国研究中心 1 个：Mianyang
- 仅邀请入组NCT06616727The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM中国研究中心 1 个：Beijing
- 招募中NCT06220552The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma中国研究中心 1 个：Zhuhai
- 仅邀请入组NCT06690216Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors中国研究中心 1 个：Jinan
- 招募中NCT06327451Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma中国研究中心 1 个：Tianjin
- 尚未开始招募NCT06368934Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma中国研究中心 1 个：Shanghai
- 招募中NCT05990556Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients中国研究中心 1 个：Guangzhou
- 招募中NCT06740955Hypofractionated Radiotherapy中国研究中心 1 个：Changchun
- 仅邀请入组NCT07130149Sonodynamic-Chemoradiotherapy Integration in Glioblastoma中国研究中心 1 个：Zhengzhou
- 招募中NCT06598787A Study of BL-B01D1 in Patients With Recurrent Glioblastoma中国研究中心 1 个：Beijing
- 招募中NCT06640582TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas中国研究中心 1 个：Beijing
- 招募中NCT06757153Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients中国研究中心 1 个：Wuhan
- 招募中NCT06936046Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression中国研究中心 1 个：Hangzhou
另有 32 项未列出。
其他状态的试验（90 项）
- 已完成NCT00870181ADV-TK Improves Outcome of Recurrent High-Grade Glioma中国研究中心 1 个：Beijing
- 已完成NCT03388372Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma中国研究中心 5 个：Guangdong、Guangzhou、Shenzhen
- 状态未知NCT01567202Study of DC Vaccination Against Glioblastoma中国研究中心 1 个：Shanghai
- 状态未知NCT01637753Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma中国研究中心 1 个：Guangzhou
- 状态未知NCT01656980Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma中国研究中心 1 个：Beijing
- 状态未知NCT01765088A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas中国研究中心 1 个：Guangzhou
- 已完成NCT02122822Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96中国研究中心 1 个：Beijing
- 状态未知NCT01939574A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma中国研究中心 1 个：Jinan
- 状态未知NCT02047058Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics中国研究中心 1 个：Guangzhou
- 状态未知NCT02520635Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients中国研究中心 1 个：Beijing
- 已完成NCT02573324A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification中国研究中心 14 个：Beijing、Changsha、Fuzhou、Guangzhou、Hangzhou、Hefei 等 12 地
- 状态未知NCT02629757A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas中国研究中心 1 个：Guangzhou
- 已完成NCT02698280Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma中国研究中心 1 个：Shanghai
- 状态未知NCT02910804IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Glioblastoma中国研究中心 1 个：Beijing
- 状态未知NCT05600491A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme中国研究中心 1 个：Guangzhou
- 状态未知NCT02663440Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme中国研究中心 1 个：Hangzhou
- 已完成NCT02709616Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)中国研究中心 1 个：Guangzhou
- 已完成NCT02808364Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)中国研究中心 1 个：Guangzhou
- 已完成NCT03660761Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors中国研究中心 1 个：Jinan
- 已完成NCT02728349Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma中国研究中心 1 个：Beijing
- 状态未知NCT02844062Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme中国研究中心 1 个：Beijing
- 状态未知NCT02937844Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme中国研究中心 1 个：Beijing
- 状态未知NCT02939378Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study中国研究中心 1 个：Beijing
- 进行中·不再招募NCT02685605Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme中国研究中心 1 个：Beijing
- 状态未知NCT03347097Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme中国研究中心 1 个：Shanghai
- 已完成NCT05476341A Phase I Clinical Trial of Bevacizumab Injection中国研究中心 1 个：Changchun
- 状态未知NCT03567135Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma中国研究中心 1 个：Fuzhou
- 已完成NCT03050736Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression中国研究中心 1 个：Guangzhou
- 状态未知NCT03231501HMPL-813 in Treating Patients With Glioblastoma中国研究中心 2 个：Hanzhou、Shanghai
- 状态未知NCT03160599Restricted Calorie Ketogenic Diet as a Treatment in Malignant Tumors中国研究中心 1 个：Guangzhou
- 状态未知NCT03392545Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1)中国研究中心 1 个：Beijing
- 已完成NCT06562621Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma中国研究中心 1 个：Beijing
- 进行中·不再招募NCT06105619A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).中国研究中心 1 个：Beijing
- 状态未知NCT03734913A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors中国研究中心 1 个：Changchun
- 已完成NCT04119674Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma中国研究中心 1 个：Hangzhou
- 状态未知NCT04045847CD147-CART Cells in Patients With Recurrent Malignant Glioma.中国研究中心 1 个：Xi'an
- 状态未知NCT04004975Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib中国研究中心 1 个：Jinan
- 状态未知NCT03650257A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96中国研究中心 1 个：Beijing
- 状态未知NCT04157478Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma中国研究中心 7 个：Guilin、Liuzhou、Nanning、Yulin
- 已撤回NCT04270461NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors中国研究中心 1 个：Jiujiang
另有 50 项未列出。
中国境外的在招试验 427L2
这些试验在中国没有研究中心，通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处：看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生，或据此进一步查该药是否已在境外获批、是否有拓展性用药（expanded access）通道。
美国93法国15德国12英国10意大利9瑞士8加拿大7荷兰7澳大利亚5比利时5瑞典5丹麦4奥地利3波兰3另有 12 个国家/地区
CT.gov 报告命中 427 项，此处取回并展示最近的 15 项。
- 尚未开始招募NCT07751744Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
- 尚未开始招募NCT07546669Efficacy of Zoster Vaccination in Glioblastoma Patients
- 尚未开始招募NCT04373785NG101m Adjuvant Therapy in Glioblastoma Patients美国
- 尚未开始招募NCT01777919Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform希腊
- 尚未开始招募NCT04933422CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)
- 尚未开始招募NCT07274787Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma美国
- 尚未开始招募NCT07579208A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma美国
- 尚未开始招募NCT07715097Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma
- 尚未开始招募NCT07769918Hypoxia-targeted Radiotherapy Boost for GBM美国
- 尚未开始招募NCT07762716Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy美国
- 尚未开始招募NCT07620548Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas美国
- 招募中NCT04903795BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma美国
- 尚未开始招募NCT07754734STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation
- 尚未开始招募NCT07521657Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma美国
- 招募中NCT06492486Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow印度
外部标识与链接
发现这一页有错误？告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学：Orphanet（CC BY 4.0）
- 中文病名：Orphanet 中文包，冻结于 2020-06-01
- 表型中文标签：HPO 简体中文翻译（CHPO 上游成果）